

## **Phase I dose-escalation study of F50067, a humanized anti-CXCR4 monoclonal antibody alone and in combination with Lenalidomide and low-dose dexamethasone, in relapsed or refractory multiple myeloma**

### **SUPPLEMENTARY MATERIALS**

**Supplementary Table 1: Patients' characteristics by arm and dose level (*n* (%) unless specified).** See Supplementary\_ Table\_1